Nuvectis Pharma, Inc.
NVCTHealthcare|Biotechnology|US
$20.91
+3.15 (+17.74%)
DCF Value
$1.18
Tangible Book / Share
$4.30
Cash / Share
$4.78
Financials
Financial Snapshot
Market Cap
$682.6M
Enterprise Value
$541.9M
Revenue (TTM)
$0.00
Net Income (TTM)
-$50.5M
Cash & Investments
$140.7M
Net Cash
$140.7M
Free Cash Flow (TTM)
-$40.3M
Operating CF (TTM)
-$40.3M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$140.7M
Quarterly Burn
$10.1M
Monthly Burn
$3.4M
Est. Runway
~14.0 quarters
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $0.00 | $5.7M | $20.0M | $19.1M | $18.5M | $31.6M | $140.7M | |
| Operating Cash Flow | $0.00 | -$9.5M | -$13.6M | -$16.0M | -$12.2M | -$16.0M | -$40.3M | |
| Free Cash Flow | $0.00 | -$9.5M | -$13.6M | -$16.0M | -$12.2M | -$16.0M | -$40.3M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $0.00 | $15.2M | $27.8M | $15.1M | $11.7M | $29.1M | $145.6M |
R&D Spending
R&D (TTM)
$41.2M
R&D Intensity
—
R&D Growth vs Prior
+127.2%
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $0.00 | $9.5M | $13.2M | $15.4M | $12.9M | $18.2M | $41.2M | |
| SG&A | $10.0K | $3.3M | $6.0M | $7.5M | $6.9M | $9.4M | $10.9M |
Income Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $0.00 | $9.5M | $13.2M | $15.4M | $12.9M | $18.2M | $41.2M | |
| SG&A | $10.0K | $3.3M | $6.0M | $7.5M | $6.9M | $9.4M | $10.9M | |
| Operating Income | -$10.0K | -$12.9M | -$19.2M | -$22.9M | -$19.8M | -$27.6M | -$52.1M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$10.0K | -$12.9M | -$19.1M | -$22.3M | -$19.0M | -$26.4M | -$50.5M | |
| Net Income | -$10.0K | -$12.9M | -$19.1M | -$22.3M | -$19.0M | -$26.4M | -$50.5M | |
| EPS (Diluted) | -0.00 | -1.09 | -1.51 | -1.43 | -1.11 | -1.32 | -1.89 | |
| EBITDA | -$10.0K | -$12.9M | -$19.1M | -$22.3M | -$19.0M | -$26.4M | -$52.5M | |
| Shares Out. (M) | 12.72 | 12.72 | 12.66 | 15.56 | 17.11 | 21.81 | 29.47 |
Balance Sheet
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $0.00 | $5.7M | $20.0M | $19.1M | $18.5M | $31.6M | $140.7M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $0.00 | $5.8M | $20.4M | $19.2M | $18.6M | $31.7M | $140.8M | |
| Total Assets | $0.00 | $6.7M | $20.4M | $19.2M | $18.6M | $31.7M | $140.8M | |
| Total Current Liabilities | $10.0K | $2.4M | $6.2M | $7.0M | $8.9M | $13.3M | $14.2M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $10.0K | $17.7M | $6.2M | $7.0M | $8.9M | $13.3M | $14.2M | |
| Stockholders' Equity | -$10.0K | -$11.0M | $14.2M | $12.2M | $9.7M | $18.4M | $126.6M | |
| Retained Earnings | -$10.0K | -$12.9M | -$32.0M | -$54.2M | -$73.2M | -$99.7M | -$142.8M |
Cash Flow Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $0.00 | -$9.5M | -$13.6M | -$16.0M | -$12.2M | -$16.0M | -$40.3M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Free Cash Flow | $0.00 | -$9.5M | -$13.6M | -$16.0M | -$12.2M | -$16.0M | -$40.3M | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $0.00 | $15.2M | $27.8M | $15.1M | $11.7M | $29.1M | $145.6M | |
| Issuance of Stock | $0.00 | $15.2M | $31.9M | $5.3M | $12.0M | $31.2M | $154.7M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $1.9M | $1.7M | $4.7M | $4.9M | $6.0M | $7.5M | |
| Net Change in Cash | $0.00 | $5.7M | $14.3M | -$867.0K | -$593.0K | $13.1M | $105.3M |
Dilution Tracker
Shares outstanding grew 71.5% over 5 years — significant dilution
Shares Outstanding
33M
5-Year Share Growth
+71.5%
Stock Issuance (TTM)
$154.7M
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 12.72 | 12.72 | 12.66 | 15.56 | 17.11 | 21.81 | 29.47 | |
| Change vs Prior % | — | 0.0% | -0.5% | 22.9% | 10.0% | 27.5% | 35.1% | |
| Stock Issuance | $0.00 | $15.2M | $31.9M | $5.3M | $12.0M | $31.2M | $154.7M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $1.9M | $1.7M | $4.7M | $4.9M | $6.0M | $7.5M |
Margins & Profitability
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| ROE % | 100.0% | 117.1% | -134.2% | -182.4% | -195.6% | -143.6% | -119.9% | |
| ROA % | 0.0% | -193.6% | -93.5% | -116.0% | -102.1% | -83.4% | -35.8% | |
| ROIC % | 100.0% | -304.2% | -135.3% | -187.7% | -204.3% | -149.8% | -41.2% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -128840.0% | -49.2% | -19.0% | 13.3% | -38.9% | |
| Net Income | 0.0% | -128800.0% | -48.1% | -16.6% | 14.6% | -39.2% | |
| EPS (Diluted) | 0.0% | -136150.0% | -38.5% | 5.3% | 22.4% | -18.9% | |
| Operating Cash Flow | 0.0% | 0.0% | -42.7% | -17.7% | 23.2% | -30.7% | |
| Free Cash Flow | 0.0% | 0.0% | -42.7% | -17.7% | 23.2% | -30.7% | |
| R&D Expense | 0.0% | 0.0% | 38.6% | 16.3% | -16.0% | 40.5% | |
| SG&A Expense | 0.0% | 33390.0% | 79.4% | 25.1% | -7.8% | 36.0% | |
| Total Assets | 0.0% | 0.0% | 206.5% | -6.0% | -3.0% | 70.4% | |
| Book Value / Share | 0.0% | -109980.0% | 229.8% | -30.2% | -27.6% | 48.7% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | 0.0% | 0.0% | -0.5% | 22.9% | 10.0% | 27.5% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B4.87
10Y Low / Med / High6.68 / 9.53 / 10.63
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$1.18
Tangible Book / Share
$4.30
Net Current Assets / Share
$3.88
Graham Net-Net
$4.29
Cash / Share
$4.78
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -4062.50 | -2.98 | -4.97 | -5.83 | -4.87 | -5.72 | -11.06 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -4133.28 | -3.75 | 6.68 | 10.63 | 9.53 | 8.94 | 4.87 | |
| EV/EBITDA | -4133.28 | -2.76 | -3.93 | -4.97 | -3.90 | -5.03 | -10.32 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
27.28
Safe
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $3.0M | $26.0M | $4.4M |
| Net Income | -$26.2M | -$30.0M | -$42.4M |
| EPS | $-1.48 | $-1.32 | $-1.47 |
| # Analysts (EPS) | 4 | 5 | 5 |